FDA Issues New Safety Standards for Gene Editing Therapies
New FDA guidance provides roadmap for safer genome editing treatments, potentially accelerating development of therapies for genetic diseases.
802 articles
New FDA guidance provides roadmap for safer genome editing treatments, potentially accelerating development of therapies for genetic diseases.
FDA encourages expanded testosterone therapy trials for men with idiopathic hypogonadism experiencing low libido based on emerging clinical evidence.
Two experimental cancer drugs targeting immune checkpoints achieved high response rates in advanced gynecologic cancers with manageable side effects.
Global liver disease cases projected to surge 42% by 2050, while new ultrasound monitoring shows promise for inflammatory bowel conditions.
Controversial study pooling failed and successful amyloid drugs draws criticism from Alzheimer's researchers for misleading conclusions.
Researchers develop obesity drug targeting different hormones while Lilly's pill shows cardiovascular benefits in new trial.
Breakthrough therapy targeting hypoxic-ischemic encephalopathy in newborns receives significant funding, potentially becoming first HIE drug.
New research shows targeting ghrelin receptors improves muscle function and reduces sarcopenia in aging mice through better mitochondrial health.
New collaboration aims to create pancreatic islet cell therapy that could eliminate need for daily insulin injections in type 1 diabetes patients.
Biotech company doses first patient with AIR-001, an RNA-editing treatment that could offer reversible genetic correction for inherited conditions.
Solengepras takes a novel approach to Parkinson's treatment, reducing daily motor symptoms and improving sleep by targeting brain circuitry.
Swiss partnership launches cellular avatars that predict immune responses and aging patterns using AI-powered modeling.